195 related articles for article (PubMed ID: 25319441)
1. Effect of switching therapy to pegaptanib in eyes with the persistent cases of exudative age-related macular degeneration.
Shiragami C; Ono A; Kobayashi M; Manabe S; Yamashita A; Shiraga F
Medicine (Baltimore); 2014 Oct; 93(18):e116. PubMed ID: 25319441
[TBL] [Abstract][Full Text] [Related]
2. Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments.
Lommatzsch A; Heimes B; Gutfleisch M; Spital G; Zeimer M; Pauleikhoff D
Eye (Lond); 2009 Dec; 23(12):2163-8. PubMed ID: 19197318
[TBL] [Abstract][Full Text] [Related]
3. Variable response of vascularized pigment epithelial detachments to ranibizumab based on lesion subtypes, including polypoidal choroidal vasculopathy.
Inoue M; Arakawa A; Yamane S; Kadonosono K
Retina; 2013 May; 33(5):990-7. PubMed ID: 23446653
[TBL] [Abstract][Full Text] [Related]
4. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
Spielberg L; Leys A
Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
[TBL] [Abstract][Full Text] [Related]
5. [Intravitreal ranibizumab in combination with verteporfin photodynamic therapy in neovascular macular degeneration].
Soucek P; Soucková I
Cesk Slov Oftalmol; 2008 Jul; 64(4):135-40. PubMed ID: 18780651
[TBL] [Abstract][Full Text] [Related]
6. Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis.
Canan H; Sızmaz S; Altan-Yaycıoğlu R; Sarıtürk C; Yılmaz G
Clin Interv Aging; 2014; 9():141-5. PubMed ID: 24453484
[TBL] [Abstract][Full Text] [Related]
7. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.
Cho H; Shah CP; Weber M; Heier JS
Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal ranibizumab therapy versus photodynamic therapy for idiopathic choroidal neovascularization: a comparative study on visual acuity, retinal and choroidal thickness.
Shi X; Wei W; Zhang C
Chin Med J (Engl); 2014; 127(12):2279-85. PubMed ID: 24931242
[TBL] [Abstract][Full Text] [Related]
10. A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration.
Sivaprasad S; Patra S; DaCosta J; Adewoyin T; Shona O; Pearce E; Chong NV
Ophthalmologica; 2011; 225(4):200-6. PubMed ID: 21293163
[TBL] [Abstract][Full Text] [Related]
11. Effect of ranibizumab on serous and vascular pigment epithelial detachments associated with exudative age-related macular degeneration.
Panos GD; Gatzioufas Z; Petropoulos IK; Dardabounis D; Thumann G; Hafezi F
Drug Des Devel Ther; 2013; 7():565-9. PubMed ID: 23874084
[TBL] [Abstract][Full Text] [Related]
12. Vascularized retinal pigment epithelial detachment in age-related macular degeneration: treatment and RPE tear incidence.
Introini U; Torres Gimeno A; Scotti F; Setaccioli M; Giatsidis S; Bandello F
Graefes Arch Clin Exp Ophthalmol; 2012 Sep; 250(9):1283-92. PubMed ID: 22350060
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up.
Matsumiya W; Honda S; Kusuhara S; Tsukahara Y; Negi A
BMC Ophthalmol; 2013 Apr; 13():10. PubMed ID: 23557322
[TBL] [Abstract][Full Text] [Related]
14. Combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation.
Saito M; Iida T; Kano M
Am J Ophthalmol; 2012 Mar; 153(3):504-514.e1. PubMed ID: 22078902
[TBL] [Abstract][Full Text] [Related]
15. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration.
Lee SJ; Koh HJ
Ophthalmology; 2011 Jan; 118(1):101-10. PubMed ID: 20678805
[TBL] [Abstract][Full Text] [Related]
16. Long-term visual outcome of pigment epithelial tears in association with anti-VEGF therapy of pigment epithelial detachment in AMD.
Gutfleisch M; Heimes B; Schumacher M; Dietzel M; Lommatzsch A; Bird A; Pauleikhoff D
Eye (Lond); 2011 Sep; 25(9):1181-6. PubMed ID: 21701525
[TBL] [Abstract][Full Text] [Related]
17. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
18. Bilateral intravitreal bevacizumab injection for exudative age-related macular degeneration: effect of baseline visual acuity.
Jonas JB; Tao Y; Rensch F
J Ocul Pharmacol Ther; 2011 Aug; 27(4):401-5. PubMed ID: 21810019
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size.
Nishimura Y; Taguchi M; Nagai T; Fujihara M; Honda S; Uenishi M
Clin Ophthalmol; 2012; 6():365-8. PubMed ID: 22419857
[TBL] [Abstract][Full Text] [Related]
20. Subjective perception versus objective outcome after intravitreal ranibizumab for exudative AMD.
Koch KR; Muether PS; Hermann MM; Hoerster R; Kirchhof B; Fauser S
Graefes Arch Clin Exp Ophthalmol; 2012 Feb; 250(2):201-9. PubMed ID: 21901296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
